retatrutide triple agonist obesity trial 🚨 HOT OFF THE PRESS: Phase 3 data has arrived — and the medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average Lilly's triple agonist, retatrutide, delivered

Conclusion PROM developers consider it feasible to involve children younger than 8-years-old in the qualitative development of PROMs in QoL research

PMID: 139 TzeraviniE.SimatiS.AnastasiouI

Best of all, Ro offers new patients ongoing support and a $50 credit with their results, helping them navigate their weight loss program from start to finish

This is not its primary application, but it is a welcome bonus for anyone dealing with knee or hip discomfort during their weight loss journey

Outside of a clinical trial, access to an unlicensed investigational medicine such as retatrutide would only be possible under specific MHRA frameworks for example, the Early Access to Medicines Scheme (EAMS) , which requires a positive scientific opinion from the MHRA before use outside trials can be considered